Kala Bio, Inc. (LSX:A4243T) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock (or pre-funded warrants in lieu thereof) Closed: US$10M raised · US$1 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Repay certain indebtedness and general corporate purposes | Dec 5, 2025 |
| Private placement of non-voting convertible preferred stock Tranche closed: US$1.8M raised Buyers: David E. Lazar ($6 million of non-voting convertible preferred stock; $1.8 million of Series AA preferred in first closing, $4.2 million of Series AAA preferred in second closing) Insiders: Investor David E. Lazar was appointed Chief Executive Officer and Chairman of the Board effective immediately. Use of proceeds: Evaluation and redevelopment of product candidates and patent portfolio, working capital and funding for a potential strategic transaction | Dec 1, 2025 |
| Private placement of common stock and Series I Convertible Non-Redeemable Preferred Stock Announced: about US$10.75M · US$6.44 a share Buyers: SR One; Cormorant Asset Management; Woodline Partners Use of proceeds: Advance clinical development of KPI-012 for persistent corneal epithelial defect and general corporate purposes | Dec 30, 2024 |